Business Close to Home

Acquisitions · United States

Why is part of the Ollin buyout price tied to results?

Johnson & Johnson agreed to buy an eye-drug developer for US$2.2 billion at closing. The rest depends on what happens next, and a separate agreement brings in Blackstone to fund development.

Suppose you want to buy a bookshop. The owner points across the road to a building site. A school is due to open there next year, and the owner expects students to come in for books. You can agree on a price for the shop as it stands and offer to pay more if the school opens and the shop reaches an agreed sales target. The school opening and the students buying books are two separate events.

Johnson & Johnson agreed to buy Ollin Biosciences, a company developing treatments for serious eye disease, on similar terms. It would pay US$2.2 billion at closing and up to about US$1.125 billion more if agreed targets are met. The companies announced the agreement on 16 November 2026 and expected to close by year-end, subject to required approvals and other conditions. As of 19 November, there had been no public announcement of a closing.[1][2]

Who would pay whom, and when?
  1. At closingJohnson & Johnson would pay Ollin’s sellers US$2.2 billion.
  2. If targets are metJohnson & Johnson could pay the sellers up to about US$1.125 billion more.
  3. Under a separate agreementAfter closing, Blackstone funds would provide US$750 million to Johnson & Johnson over several years for development.

What has to happen before the sellers get the rest?

Closing is when ownership changes hands. If the deal closes, Johnson & Johnson will pay US$2.2 billion and take over Ollin’s development work. One of its main drug candidates is already in late-stage trials. It still needs approval before it can be sold in the relevant markets.[1][2]

The deal has two kinds of milestones, or targets that trigger a payment. Some depend on progress with regulators. Others depend on how the drug performs commercially. A regulator can allow a drug to go on sale, while the number of buyers remains uncertain. Johnson & Johnson published a combined cap for the extra payments. The individual amounts and exact triggers remain private.[1]

Who would pay for the remaining development?

Funds managed by Blackstone Life Sciences agreed to provide Johnson & Johnson with US$750 million over several years to pay for late-stage development. In return, Blackstone would be eligible for payments linked to regulatory progress and sales, along with royalties at a single-digit percentage rate. Its funding starts only if the Ollin deal closes.[1][3]

Follow the two payments. Johnson & Johnson would pay Ollin’s sellers to buy the company. Blackstone would pay Johnson & Johnson to fund part of the work that follows. The sellers would receive cash at closing and could receive more later. Blackstone would put up money for development and get a chance to earn it back under its own agreement. Approval and sales can affect both sets of payments.[1][3]

When is it hard to tie the price to results?

Back at the bookshop, suppose you start ringing up café and book sales at the same till. How does the former owner check what the books brought in? If you shorten the opening hours, can the former owner insist that you stay open? An extra payment is easier to agree on when both sides can check the result and know who controls the decisions that affect it.

Johnson & Johnson and Ollin agreed on what the buyer would pay to take over at closing. They left part of the price to be determined by what happens to the drug after that. The sellers would receive a fixed amount at closing and could still receive more. The buyer would owe the extra money only if the agreed results materialise.[1]

Acquisitions and the sharing of risk

Ollin’s sale shows how a buyer, sellers and a development funder can each take on a different part of the same uncertainty. To understand how the buyer earns its regular income, follow the separate transactions in which it sells drugs, devices and services.

Sources

  1. Johnson & Johnson’s announcement of the proposed Ollin acquisition
  2. Ollin Biosciences’ announcement of the acquisition agreement
  3. Blackstone Life Sciences’ announcement of the US$750 million funding agreement